Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
基本信息
- 批准号:10194393
- 负责人:
- 金额:$ 203.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-03 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AML/MDSAcute Lymphocytic LeukemiaAcute Myelocytic LeukemiaAcute T Cell LeukemiaAllogenicAnimal ModelAntibody TherapyBasic ScienceBiometryBispecific AntibodiesCD3 AntigensCXCR4 geneCancer Research ProjectClinicalClinical TrialsCollaborationsDataDecitabineDevelopmentDisabled PersonsDysmyelopoietic SyndromesFemaleGenomicsGoalsGrant ReviewHematopoiesisImmunologyImmunotherapyInfrastructureInstitutionJointsLaboratoriesMemoryMentorsMinorityMolecularMolecular ProfilingMulti-Institutional Clinical TrialMutateMutationNatural Killer CellsNelarabineOralPathway interactionsPatientsProgram ReviewsPropertyRNA SplicingRefractoryRelapseResearchResearch PersonnelResearch Project GrantsResistanceResourcesSalvage TherapySignal TransductionSpecialized Program of Research ExcellenceTP53 geneTestingTherapeuticTherapeutic TrialsTrainingTraining ProgramsTranslational ResearchUniversitiesWashingtonacute T-cell lymphoblastic leukemia cellantibody conjugatebasecancer genomicscareerconditioningcytokinefirst-in-humanfundamental researchhematopoietic cell transplantationinhibitor/antagonistinnovationleukemialeukemia treatmentmeetingsmutantnovelnovel markernovel therapeuticspeerpre-clinicalpreclinical studyprogramsrecruitresearch and developmentresponsetargeted agenttargeted treatmenttranslational cancer research
项目摘要
ABSTRACT
The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that
focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding
group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we
leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational
research in leukemia. Our long-term goal is to develop novel biomarkers and treatments for leukemias and
myelodysplastic syndromes and to develop and promote innovative translational leukemia research. To achieve
these goals, the following specific aims are proposed.
Aim 1. We will exploit institutional expertise in cancer genomics, immunology, and hematopoiesis to
develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes. Basic research
at WUSM has led to the development of the following five translational research projects, all featuring innovative
investigator-initiated therapeutic trials for leukemias or MDS.
· Project 1. Molecular determinants of decitabine responsiveness
· Project 2. Targeted therapies for T cell acute lymphoblastic leukemia (T-ALL)
· Project 3. Novel therapies for splicesome-mutant MDS
· Project 4. Bi-specific antibody-based therapies for AML
· Project 5. Memory-like NK cell augmented hematopoietic cell transplantation for AML
Aim 2. We will enhance the infrastructure that supports translational leukemia research. This SPORE
will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B.
Biostatistics; and 3) Core C. Administration.
Aim 3. We will recruit and train new investigators in translational research. This SPORE will support
a Career Enhancement Program (CEP) to recruit and mentor new investigators in translational leukemia
research. The SPORE has established a successful minority post-baccalaureate training program. The SPORE
also will support a Developmental Research Program (DRP) to support innovative translational concepts.
Aim 4. We will facilitate inter-SPORE collaboration. Four of the SPORE projects include multi-institutional
clinical trials, including three at other Leukemia SPORE institutions. We have established CEP educational
exchange and grant review programs with peer Leukemia SPORE institutions. We will continue to organize and
participate in joint meetings of Leukemia SPOREs at MD Anderson and Harvard.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniel C Link其他文献
Enhancing hematopoietic growth factor performance
增强造血生长因子性能
- DOI:
10.1038/nm.3022 - 发表时间:
2012-12-06 - 期刊:
- 影响因子:50.000
- 作者:
Yen-Michael S Hsu;Daniel C Link - 通讯作者:
Daniel C Link
Daniel C Link的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniel C Link', 18)}}的其他基金
Identification of new genetic causes of congenital neutropenia
先天性中性粒细胞减少症新遗传原因的鉴定
- 批准号:
10621903 - 财政年份:2020
- 资助金额:
$ 203.6万 - 项目类别:
Identification of new genetic causes of congenital neutropenia
先天性中性粒细胞减少症新遗传原因的鉴定
- 批准号:
10159977 - 财政年份:2020
- 资助金额:
$ 203.6万 - 项目类别:
Identification of new genetic causes of congenital neutropenia
先天性中性粒细胞减少症新遗传原因的鉴定
- 批准号:
10399626 - 财政年份:2020
- 资助金额:
$ 203.6万 - 项目类别:
Single Cell Spatial Characterization of the Human Bone Marrow Microenvironment
人类骨髓微环境的单细胞空间表征
- 批准号:
10115110 - 财政年份:2020
- 资助金额:
$ 203.6万 - 项目类别:
Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
- 批准号:
10439617 - 财政年份:2013
- 资助金额:
$ 203.6万 - 项目类别:
Specialized Program Of Research Excellence (SPORE) in Leukemia
白血病专业卓越研究计划 (SPORE)
- 批准号:
9307740 - 财政年份:2013
- 资助金额:
$ 203.6万 - 项目类别:
Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
- 批准号:
9756314 - 财政年份:2013
- 资助金额:
$ 203.6万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 203.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 203.6万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 203.6万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 203.6万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 203.6万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 203.6万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 203.6万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 203.6万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 203.6万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 203.6万 - 项目类别:














{{item.name}}会员




